Humira. Stelara. Remicade. The list of blockbuster biologic drugs for the autoimmune conditions Crohn’s disease and ulcerative colitis is long, and the amount of competition in the market could seem daunting to newcomers. For Teva Pharmaceuticals, long known as a generics powerhouse, that isn’t enough to shake the hopes that its late-stage-ready and Sanofi-partnered anti-TL1A candidate duvakitug could contribute to the company’s turnaround effort in innovative medicine.

“This is a brand new biologic class, and the most potent and selective in ulcerative colitis and Crohn’s disease so far,” said Dr. Eric Hughes, chief medical officer and executive vice president of global R&D at Teva. “Even in the biggest indications in immunology, there’s plenty of room — it’s one of the biggest therapeutic growth areas out there, and the most valuable.”

It wasn’t too long ago that the company was in dire straits, having dropped a little too much cash on an acquisition that almost took the ship down with it. But now, with a strategic shift toward innovative R&D, Teva is on a path to redemption. Today, we’re featuring a conversation with Hughes about how those efforts came about and why a changing mindset could set the company up for a brighter future.

We’re also exploring the trials and tribulations of the psychedelic therapy space, and why one company is emerging as a front-runner.

Thanks for reading.